Top

Published in:

01-06-2011

Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?

Authors: Christian G. Chaussy, Stefan F. Thüroff

Published in: Current Urology Reports | Issue 3/2011

Abstract

High-intensity focused ultrasound (HIFU) is an emerging, noninvasive, local treatment of prostate cancer with 15 years of clinical experience, during which about 30,000 HIFU treatments have been performed worldwide. In this paper, we review relevant publications regarding the means by which new and old prostate cancer technologies are evaluated, the outcomes of HIFU by Ablatherm (EDAP TMS, Lyon, France), and the evolution currently underway regarding how prostate cancer is diagnosed and treated. We show the potential of HIFU to be used as local therapy for men with any stage of prostate cancer and how this additional therapeutic option can fit within the future armamentarium of a sequential multimodal therapy concept.

Marberger M. Prostate cancer 2008. Challenges in diagnostic and management. Europ Urol. 2009;8 Suppl 3:1989–96.

van Leeuwen PJ, Connolly D, Tammela TL, et al. Balancing the harms and benefits of early detection of prostate cancer. Cancer. 2010;116:4857–65.PubMedCrossRef

Chaussy C, Thueroff S. The use of high-intensity focused ultrasound in prostate cancer. In: Ukimura O, Gill IS, editors. Contemporary Interventional Ultrasonography in Urology, Chapter 7. London: Springer; 2009. p. 63–73.CrossRef

Chaussy C, Thueroff S, Rebillard X, et al. Technology insight: high-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol. 2005;2(4):191–8.PubMedCrossRef

Chaussy C, Thueroff S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol. 2001;15:437–40.PubMedCrossRef

Gelet A, Chapelon JY, Bouvier R, et al. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol. 2001;40:124–9.PubMedCrossRef

Poissonnier L, Gelet A, Chapelon JY, et al. Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or +10 ng/ml). Prog Urol. 2003;13:60–72.PubMed

Thüroff S, Chaussy C, Vallencien G, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol. 2003;17:673–7.PubMedCrossRef

Blana A, Walter B, Rogenhofer S, et al. High intensity focused ultrasound for the treatment of localized prostate cancer. Urology. 2004;63(2):297–300.PubMedCrossRef

10.

Ficarra V, Antoniolli SZ, Novara G, et al. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int. 2006;98:1193–8.PubMedCrossRef

11.

Poissonnier L, Chapelon JY, Rouvière O, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol. 2007;51:381–7.PubMedCrossRef

12.

Blana A, Murat FJ, Walter B, et al. First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol. 2008;53(6):1194–201.PubMedCrossRef

13.

• Blana A, Brown SC, Chaussy C, et al. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. Int BJU. 2009;104(8):1058–62. This article provides the outcome from a large registry of HIFU patients, which showed good 5-year results in low- and medium-risk patients. CrossRef

14.

Crouzet S, Rebillard X, Chevallier D, et al. Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol. 2010;58:559–66.PubMedCrossRef

15.

Agarwal PK, Sadetsky N, Konety BR, et al. Cancer of the prostate strategic urological research endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;112:307–14.PubMedCrossRef

16.

Chaussy CG, Thueroff S. Transrectal high-intensity focused ultrasound for local treatment of Prostate Cancer. Urologe A. 2009;48(7):710–8. Review. German.PubMedCrossRef

17.

Klotz L. Active surveillance for prostate cancer: patient selection and management. Curr Oncol. 2010;17 Suppl 2:11–7.

18.

Soloway MS, Soloway CT, Eldefrawy A, et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Europ Urol. 2010;58(6):831–35.CrossRef

19.

Klotz L. Active surveillance for Prostate Cancer: For whom ? J Clin Oncol. 2005;23(32):8165–9.PubMedCrossRef

20.

Roemling MJ, Roobol MW, Kattan TH, et al. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer. 2007;110:2218–21.CrossRef

21.

• Onik G, Narayan P, Vaughan D, et al. Focal nerve sparing cryoablation for the treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60:109–14. The primary idea of carrying out a focal treatment goes back to Onik et al. They used Cryoablation to offer patients a “prostate lumpectomy”.PubMedCrossRef

22.

Bahn DK, Silverman P, Lee Sr F, et al. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol. 2006;20(9):688–92.PubMedCrossRef

23.

Onik G, Vaughan D, Lotenfoe R, et al. Male lumpectomy: focal therapy for prostate cancer using cryoablation. Urology. 2007;70:18–21.CrossRef

24.

Ellis D, Manny TB, Rewcastle JC. ocal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology. 2007;70:9–15.PubMedCrossRef

25.

Muto S, Takashi Y, Saito K, et al. Focal therapy with High-intensity-focused-ultrasound in the treatment of localised prostate cancer. Jpn J Clin Oncol. 2008;38:192–99.PubMedCrossRef

26.

Vallancien G, Prapotnich D, Cathelineau X, et al. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol. 2004;171(Pt 1):2265–7.PubMedCrossRef

27.

• Chaussy C, Thüroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep. 2003;4:248–52. Provides outcome data for HIFU with pre-transurethral resection of the prostate compared with HIFU alone and provides the basis for common combination therapeutic options. PubMedCrossRef

28.

Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:439–43.PubMedCrossRef

29.

Chaussy CG, Thueroff S. High-intensive focused ultrasound in localized prostate cancer. J Endourol. 2000;14:293–9.PubMedCrossRef

30.

Thüroff S, Chaussy C. High-intensity focused ultrasound: complications and adverse events. Mol Urol. 2000;4:183–7.PubMed

31.

Chaussy C, Thüroff S. High-intensity focused ultrasound in the management of prostate cancer. Expert Rev Med Devices. 2010;7:209–17.PubMedCrossRef

32.

Thüroff S, Chaussy C. High-Intensity focused ultrasound for prostate cancer. In: Li-Ming Su, Young Stephen C, editors. Early Dignosis and Treatment of Cancer: Prostate Cancer, Chapter 9. Philadelphia: Saunders Elsevier; 2008. p. 177–92.

33.

Shoji S, Nakano M, Nagata Y, Usui Y, Terachi T, Uchida T. Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int J Urol. 2010;17:715–19.PubMedCrossRef

34.

Murat FJ, Poissonnier L, Rabilloud M, et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Uro. 2009;55:640–7.CrossRef

35.

Berge V, Baco E, Karlsen SJ. A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scand J Urol Nephrol. 2010;44:223–7.PubMedCrossRef

36.

Chaussy CG, Thueroff SF. HIFU treatment of locally advanced prostate cancer. J Endourol. 2010;24 Suppl 1:PS12–2.

37.

Chaussy C, Thuroff S, Nanieva R. Hormone resistant prostate cancer treated by robotic high intensive ultrasound. J Urol. 2010;183(Suppl):e262.CrossRef

38.

• Wu F, Wang ZB, Lu P, et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol. 2004;30(9):1217–22. Research looking at the potential of HIFU to have an immunogenic role in prostate cancer. PubMedCrossRef

39.

Wu F, Wang ZB, Cao YD, et al. Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation. Ann Surg Oncol. 2007;14(3):1237–42.PubMedCrossRef

40.

Hu Z, Yang XY, Liu Y, et al. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med. 2007;5:34.PubMedCrossRef

41.

Lu P, Zhu XQ, Xu ZI, et al. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery. 2009;145(3):286–93.PubMedCrossRef

42.

Donnelly BJ, Saliken JC, Brasher PM, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer. 2010;116:323–30.PubMedCrossRef

43.

Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144–5.PubMedCrossRef

44.

Young HH. The early diagnosis and radical cure of carcinoma of the prostate: Being a study of 40 cases and presentation of a radical operation which was carried out in four cases. Bull Johns Hopkins Hosp. 1905;16:315–21.

Title: Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?
Authors: Christian G. Chaussy
Stefan F. Thüroff
Publication date: 01-06-2011
Publisher: Current Science Inc.
Published in: Current Urology Reports / Issue 3/2011
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-011-0184-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Current Clinical Trials in Castrate-Resistant Prostate Cancer

Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity

Salvage Cryotherapy for Radiation-Recurrent Prostate Cancer: Outcomes and Complications

Use of Testosterone Replacement Therapy in Patients with Prostate Cancer

Management of Rising Prostate-specific Antigen After a Negative Biopsy

Quality of Evidence to Compare Outcomes of Open and Robot-Assisted Laparoscopic Prostatectomy